Senses Disorder TRIZ Cases

A nuclease domain degrades ribonucleoprotein particles while an Fc domain extends serum half-life, reducing anti-RNA antibodies and interferon-α induction.

Integrated cellular assays combine transcript, protein, metabolite, and phosphoprotein data to reveal disease pathways and modulators.

An anti-C5 antibody blocks membrane attack complex formation while allowing C5a generation, helping preserve ocular tissue health in AMD.

Topical lacripep uses neurotrophic signaling to regenerate corneal nerves, restore epithelial barriers, and reactivate basal tear secretion.

Organic mono- and di-carboxylic acids form crystalline S-pindolol salts that resist storage degradation and discoloration in oral formulations.

Hydrophobic phthalocyanines aggregate and accumulate poorly; elastin-like polypeptides improve delivery through temperature-responsive assembly.

Random ADC conjugation can produce variable drug-to-antibody ratios and sites; these compounds enable regioselective antibody labeling with bioorthogonal drug attachment.

Apolipoprotein-mimetic peptides promote ABCA1-mediated lipid efflux to address transport dysregulation and help clear drusen in AMD.

Tertiary amine oxide polymers help protein conjugates cross skin and epithelial barriers for transdermal, ocular, or oral delivery.

See how cyclodextrin inclusion complexes and composite excipients improve solubility and stability in pyridine phenyl eye drops.

A sulfur-based antioxidant protects epinastine in transdermal formulations, limiting related impurities while preserving effective ocular tissue concentration.

Two nucleic acid vectors join or recombine in mammalian cells to produce full-length otoferlin for genetic hearing loss.

PEG chains and selected peptide substitutions extend kinin half-life, preserve receptor activity, and support treatment in cerebral ischemia models.

This case replaces nonspecific Keap1 cysteine modification with benzothiophene-mediated Keap1–Nrf2 binding inhibition.

Fluorocarbon continuous phases help form pore-free microgels that protect therapeutic proteins from degradation while improving encapsulation.

Blocking TDO and IDO conversion of tryptophan to N-formylkynurenine reduces immunosuppressive metabolites and helps restore immune function.

Optimized cyclic compounds inhibit LRRK2, FGFR, and VEGFR and cross the blood-brain barrier, supporting potential treatment of kinase-mediated diseases.

A guanidino-containing copolymer binds mucin so eye compositions retain water and lubricity on corneal surfaces longer.

Specific substituents tune quinoline compounds for selective kinase binding, helping address side effects and resistance in disease treatment.

Targeting IGF-1R with S-ASODN-1 may lower TPO-Ab, reduce orbital inflammation, and address systemic side effects in TAO treatment.

A sn-1 specific lipase converts krill oil into LPC-DHA and LPC-EPA to address poor brain and retinal uptake from conventional omega-3 forms.

Mammalian sensorineural hair cells do not regenerate; epigenetic modifiers adjust Atoh1 expression to increase hair cell generation for hearing loss treatment.

A p62 ligand binds the ZZ domain, promotes p62–LC3 interaction, and activates selective autophagy to clear misfolded protein aggregates.

HRH1 antagonists inhibit CHOP activity and the unfolded protein response to protect retinal ganglion cells beyond intraocular pressure reduction.

Treating serum albumin with sodium octanoate or ion-exchange resins reduces associated molecules that hinder transfection and increase toxicity.

15-PGDH inhibitors target short-chain dehydrogenase activity to reduce collagen deposition and inflammatory responses in fibrotic disease.

Two split AAV8 cassettes deliver otoferlin to inner hair cells, addressing gene-size limits and restoring hearing in DFNB9 mice.

Recombinant TGFBI protein supports corneal epithelial repair in LCD models, addressing recurrent damage that persists after symptomatic or invasive treatment.

Conjugated collagen peptides combine targeted delivery with controlled release for ocular and nervous-system treatment.

Uveitis inflammation is treated with preservative-free cyclosporine in 1-perfluorobutyl-pentane, offering a topical alternative to corticosteroid side effects.

Covalently linking LHN and HC domains preserves the 310-helix interface while producing soluble neurotoxins with greater potency and longer action.

These substituted peptide analogues resist simulated gastric and intestinal fluids, then hydrolyze in plasma to release active forms for sustained therapy.

Learn how AAV particles deliver functional KCNQ4 genes or inhibitory nucleic acids to inner ear cells to address inadequate hearing-loss treatment.

Human CD30L antibodies block CD30/CD30L interactions, reducing IL-8 induction and modulating immune responses in related disorders.

When glucocorticoid therapy causes systemic side effects, S-ASODN-1 targets IGF-1R to reduce IGF-1R and anti-TPO-Ab levels in TAO.

Separating lyophilized atropine from its diluent limits aqueous hydrolysis and supports pH and concentration control before use.

Interrupted self-complementary arms create covalent closed ends for non-viral gene transfer, reducing immune response and insertional mutagenesis.

A carboxamide redox derivative targets BET proteins to suppress retinal neuroinflammation without surgical intervention.

FAM19A5 antibody therapy targets glaucoma-related inflammation, avoiding pressure reduction side effects and helping preserve retinal nerve cells.

rAAV vectors create an ocular antibody depot that maintains anti-TNF-α levels, reducing repeat injections and systemic toxicity.

By binding CFHR4, these therapeutic antibodies aim to inhibit complement activation and C3 convertase activity in Geographic Atrophy.

Small-molecule binding reshapes an aptamer riboswitch to control alternative exon splicing, switching target-gene expression on for timed regulation.

Specific antibodies inhibit Sdc2 signaling to reduce vascular leakage associated with ARDS, stroke, and inflammatory tissue injury.

Antioxidants such as cysteine suppress N-oxopyridine formation during liquid storage, helping preserve eye-drop efficacy for posterior segment disease.

Carboxymethyl cellulose increases ketorolac absorption by 130-300% while supporting longer ocular retention and reduced dosing.

Refined leaf extract uses antioxidant activity to reduce oxidative stress and protect ARPE-19 cells in diabetic retinopathy models.

An 11-day escalation from 2 mg to 9 mg before 10 mg or 20 mg maintenance reduces initial heart-rate and rhythm effects.

Exon 2-deleted AIMP2-DX2 vectors inhibit retinal cell apoptosis and support survival in degenerative eye disease models.

IL17 receptor inhibitors and rAAV vectors target retinal inflammation to slow photoreceptor and RPE degeneration in AMD.

Selective agents bind MFAP4 and block its integrin interaction to reduce collagen synthesis while avoiding broad TGF-pathway inhibition.